

ADULT AMBULATORY INFUSION ORDER 3/2023

Rituximab (RITUXAN & Biosimilars) Infusion

NAME:
BIRTHDATE:
INSURANCE:
PROVIDER NAME:
CLINIC NAME and Phone number:

**Patient identification** 

<b>W</b> eight:	kg Height: cm Allergies: Diagnosis Code:
Weight:	
	& weight are required for a complete order. Treatment Start Date:
	atment not started within 90 days, new orders with updated date/signature will be required. Otherwise,
	are valid for 1 year from signature date.** GUIDELINES FOR ORDERING:
1)	Patient name and date of birth must be on EACH page of this order form. This form will be returned if any
2)	left blank.
2)	Send FACE SHEET and complete copy of INSURANCE information. Send H&P or most recent chart note,
21	must be within the past 12 months.
	Send a copy of related lab results if not available for review in Epic.
MEDICA	
•	<b>Rituximab</b> in sodium chloride 0.9% 250 ml or 500 ml. Patient will be given biosimilar substitute (Truxima, Ruxience, Rituxan, Riabni) according to insurance coverage/preference. If insurance coverage allows,
	patient will receive drug based on pharmacy availability and the Providence Preferred Products List.
	Only check this box if it is <u>NOT okay</u> to substitute for insurance/Providence preferred product. Specific
_	
DEGLUD	product required:, specific reason why this is required:
	<b>ED Pre-screening labs:</b> (Results must be available prior to initiation of therapy, attach copy if not available Select ONE of the CBC options below. If patient schedules after timeframe selected, we will redraw lab).
-	CBC with differential Results <u>valid for <b>30 days.</b> If results not available in Epic or included with this form, a</u>
_	standing order will be placed.
	OR
	CBC with differential: Results valid for <b>60 days.</b> If results not available in Epic or included with this form, a
_	standing order will be placed. (Recommended)
✓	HCG, serum, quant. Standing lab order, our team will coordinate patient completing this prior to infusion.
	Results valid for 30 days.
✓	Hepatitis B screening: Hep B Core Antibody and Hep B Surface Antigen are recommended.
FOR FEI	MALE PATIENTS: Negative pregnancy test is required prior to receiving infusion.
	Check here ONLY If your patient <b>does not</b> need negative pregnancy test confirmed. If selected, please list
	reason for this decision:
RECOM	MENDED PRE-MEDICATIONS: (Select all that apply, to administer 30 minutes prior to infusion.)
	MethylPREDNISolone sodium succinate (solu-MEDROL) 62.5 mg/mL injection 125 mg, iv.
	Acetaminophen (TYLENOL) tablet, 650 mg, oral.
	DiphenhydrAMINE (BENADRYL) tablet, 25 mg, oral.
	OR .
	DiphenhydrAMINE (BENADRYL) iv injection, 25 mg.
DOSE: (	must select one)
	1,000 mg
	500 mg
	375 mg/m2 (accurate weight & height must be listed at top of order form)
	500 mg/m2 (accurate weight & height must be listed at top of order form)
	Other:



3/2023

Rituximab (RITUXAN & Biosimilars) Infusion

NAME: **INSURANCE:** PROVIDER NAME: **CLINIC NAME and Phone number:** 

**Patient identification** 

FREQUENCY:	(must select one)
------------	-------------------

☐ This is a ONE TIME dose only. ☐ Give two doses 14 days apart. ☐ Give once, repeat dose in 6 months (at least 168 days apart). Give two doses 14 days apart, repeat this sequence in 6 months (every 24 weeks, at least 112 days apart). ☐ Other: Give \_\_\_\_\_ dose(s), frequency: \_\_\_

# **AS NEEDED MEDICATIONS:**

✓ Sodium chloride 0.9% (NS) bolus 250 ml, Flush before and after IV medication(s) and as needed with NS. **Standard included Nursing Orders:** 

- ✓ Initial infusion: Start at 50 mg/hr. If no reaction, increase by 50 mg/hr increments every 30 min, to a maximum of 400 mg/hour. Standard subsequent infusions (if tolerate initial): Start at 100 mg/hr. If no reaction, increase by 100 mg/hr increments every 30 min, to a maximum of 400 mg/hour. If reaction occurs, stop infusion. If reaction abates, restart infusion at 50% of previous rate.
- ✓ Confirm CBC with differential was drawn within the previous month and notify LIP before first infusion of the cycle if WBC less than 3,500 or absolute neutrophils count less than 1,500.
- ✓ Confirm Hepatitis B screening addressed by LIP.
- ✓ Confirm that pregnancy test is negative (unless specified above not required).
- ✓ Confirm that prescreening tests are normal or have been addressed by Licensed Independent. Practitioner. Notify provider before starting infusion if patient has signs of active infection or history of reaction to previous infusion that has not been addressed by LIP.
- ✓ Remind patient to avoid live vaccines.
- ✓ Insert peripheral IV if no iv access.
- ✓ May use/access CVC line and give 500 units (5ml) heparin injection for central line care.
- ✓ If hypersensitivity or infusion reactions develop, temporarily hold the infusion, and notify provider immediately. Include hypersensitivity reaction order set. (See attached form).

## HYPERSENSITIVITY INFUSION REACTION ORDERS

### **STOP** infusion if:

MILD REACTION: Localized pruritus, rhinitis, localized rash, fever greater than 38 degrees C.

- 1. Stop infusion and maintain IV access with NS line.
- 2. Notify MD of symptoms and infusion reaction orders initiated.

MODERATE REACTION: Generalized pruritus, generalized flushing, rash, back pain, mild dyspnea, chills, hypotension with SBP less than 90 mmHg or greater than 20% decrease in SBP.

- 1. Stop infusion, but do not discard infusion bag/bottle unless instructed by MD that therapy is to be discontinued.
  - 2. Maintain IV access with NS line.
  - 3. Place patients in a supine position with lower extremities elevated unless respiratory distress or nausea/vomiting.
  - 4. Maintain airway.

SEVERE REACTION: Respiratory distress (bronchospasm, stridor, wheezing, persistent cough, respiratory depression, cardiac arrhythmia, chest pain, generalized urticaria (hives), syncope, gastrointestinal symptoms (abdominal pain, N/V, diarrhea), hypotension SBP less than 80 mmHg, face/throat/tongue swelling, shock, loss of consciousness.

1. Stop infusion, but do not discard bag/bottle unless instructed by MD that therapy is to be discontinued.



3/2023
Rituximab (RITUXAN & Biosimilars) Infusion

NAME:
BIRTHDATE:
INSURANCE:
PROVIDER NAME:
CLINIC NAME and Phone number:

**Patient identification** 

- 2. Stay with patient and have another nurse notify MD of symptoms and infusion reaction orders initiated.
- 3. Place patients in supine position with lower extremities elevated unless respiratory distress or nausea/vomiting.
- 4. Maintain airway.
- 5. Maintain IV access with NS line.
- 6. Inpatients: Activate code blue for loss of blood pressure, pulse, or consciousness.

#### **MEDICATIONS:**

- Acetaminophen (TYLENOL) tablet 650 mg, Oral, EVERY 4 HOURS PRN, Pain, Other, Mild reaction. Starting when released.
- DiphenhydrAMINE (Benadryl) injection, 25 mg, Intravenous, EVERY 15 MIN PRN, Moderate or severe reaction, may repeat x1. Starting when released, For 2 doses.
- Methylprednisolone sodium succinate (solu-MEDROL) 62.5mg/ml injection, 125 mg, Intravenous, ONCE PRN, Severe reaction. Starting when released, For 1 dose. Mix with 2 mL provided diluent to make 62.5 mg/mL.
- Famotidine (PEPCID) injection 20 mg, Intravenous, ONCE PRN, Moderate reaction, or anaphylaxis, starting when released. Dilute 2 mL of famotidine with 8 mL of normal saline to a final concentration of 2 mg/mL. Administer ordered dose over a period of at least 2 minutes.
- Albuterol 90 mcg/puff inhaler 2 puff, Inhalation, ONCE PRN, Severe reaction p. Starting when released, For 1 dose. Shake well. Use with spacer.
- Start oxygen. For *MODERATE* Reaction: Start 2 liters O2 per nasal cannula as needed for SpO2 less than 93%. For *SEVERE* Reaction: Start continuous pulse oximetry. Administer 6 to 8 liters per minute (LPM) via face mask, or up to 100% oxygen to maintain oxygen saturation greater than 90%.
- EPINEPHrine 1 mg/mL injection 0.3 mg. Intramuscular, EVERY 5 MIN PRN, Anaphylaxis. Starting when released, For 3 doses. Administer in the anterior lateral thigh using 1 1.5-inch needle for airway obstruction symptoms and/or hypotension.
- Sodium chloride 0.9% (NS) infusion 500ml. At 500 mL/hr., Intravenous, PRN, Moderate reaction, or anaphylaxis. Starting when released. Run wide open to gravity.

## By signing below, I represent the following:

I am responsible for the care of the patient (who is identified at the top of this form). I hold an active, unrestricted license to practice medicine in Oregon.

My physician license Number is #	and I am acting within my scope of practice and
authorized by law to order infusion of the medica identified on this form.	tions and blood products described above for the patient
Provider's printed name:	
Provider's signature:	
Date:	



3/2023

Rituximab (RITUXAN & Biosimilars) Infusion

**INSURANCE: PROVIDER NAME: CLINIC NAME and Phone number:** 

**Patient identification** 

Please of Mobility	complete the following intake ques y status	tions.				
	Independent					
	Walker					
	Wheelchair					
	Fully dependent					
Bariatric needs						
	Yes, briefly describe					
	No					
Transportation concerns						
	Yes, briefly describe					
	No					
Interpre	eter Service required					
	Yes, language					
	No					
Outpatient Infusion Services Intake Team:						
Please check the appropriate box for the patient's preferred infusion center location:						
	□ PORTLAND	Phone-503-215-6046 Fax-503-487-3582				
	☐ WILLAMETTE FALLS	Phone-503-215-6046 Fax-503-487-3582				
	☐ MEDFORD	Phone-541-732-7000 Fax-541-732-3939				
	☐ HOOD RIVER	<b>Phone-541-387-6445</b> Call for fax #				
	□ SEASIDE	Phone-503-717-7650 Fax-503-470-3146				
	□ NEWBERG	Phone-503-537-6040 Fax-503-205-8720				